Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omar Ishrak’s SPAC Buys Allurion To Support Weight-Loss System

Executive Summary

Allurion markets the Allurion Program, a unique temporary gastric balloon treatment paired with a digital health platform to support weight loss. Supported by $70m in new money from a merger with Compute Health Acquisition Corporation, the company hopes to submit a PMA to the FDA for system later this year.

You may also be interested in...



Minute Insight: Medtronic To Help Allurion Market Gastric Balloon In CEMA Region

Medtronic, an investor in Allurion, will help distribute Allurion’s inflatable gastric balloon in specific regions.

Digital Health Roundup: Omar Ishrak’s SPAC; AI In Dermatology, IVF, Imaging; Wellness Apps And Trust

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights how Alife Health is using its AI-based platform for IVF to increase chances for successful pregnancies while Barnaby Pickering discusses how AI Medical Technology is using AI to detect melanoma. Reed Miller talks about weight-loss device maker Allurion Technologies’ signed SPAC deal.

The IPO Party Is Over – How Bad Is The Hangover?

Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel